EGFR and non-small cell lung carcinoma: Previous studies (13, 14) have consistently reported that the presence of the L858R mutation in the EGFR gene correlates with improved responsiveness to EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib, erlotinib, and afatinib, as observed in patients with metastatic NSCLC.